Literature DB >> 7872061

Pharmacokinetics of clodronate in renal failure.

H Saha1, P Castren-Kortekangas, S Ojanen, A Juhakoski, J Tuominen, O Tokola, A Pasternack.   

Abstract

The pharmacokinetic parameters describing the fate of one intravenous clodronate (disodium dichloromethane diphosphonate) dose was studied in 24 normal subjects and in 24 patients with different degrees of renal insufficiency. The aim of the study was to derive data for adjustment of dosage in relation to renal function. Disodium clodronate in serum and urine samples was analyzed by capillary gas chromatography with mass-selective detection. The renal clearance (CLR) of clodronate was highly dependent on renal function and declined successively with declining glomerular filtration rate (GFR). Plasma clearance (CLP) declined, too, but to a lesser degree than CLR. The impairment of renal function resulted in decreased cumulative urinary elimination of clodronate and increased total areas under the serum concentration-time curve (AUC0-infinity). Hence, as the renal elimination of clodronate diminishes with decreasing GFR, there is a related retention of the substance. As a result of the present study, the following dosages are recommended: creatinine clearance (CLCr) from 50 to 80 ml/minute, 75-100% of normal dose; CLCr 12-50 ml/minute, 50-75% of normal dose; and ClCr < 12 ml/minute, 50% of normal dose. The results must be interpreted with caution in patients with malignancy and severe skeletal disease, in whom the nonrenal clearance may vary markedly.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7872061     DOI: 10.1002/jbmr.5650091215

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  9 in total

Review 1.  Clodronate: a review of its use in breast cancer.

Authors:  M Hurst; S Noble
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

2.  Bisphosphonate therapy in metastatic carcinoma patients with chronic renal failure: are bisphosphonates an enemy or crony?

Authors:  Fatos Dilan Koseoglu; Cagatay Arslan
Journal:  Support Care Cancer       Date:  2015-03-13       Impact factor: 3.603

Review 3.  Bisphosphonates in bone diseases.

Authors:  R W Sparidans; I M Twiss; S Talbot
Journal:  Pharm World Sci       Date:  1998-10

4.  Effect of renal function on risedronate pharmacokinetics after a single oral dose.

Authors:  D Y Mitchell; J V St Peter; R A Eusebio; K A Pallone; S C Kelly; D A Russell; J D Nesbitt; G A Thompson; J H Powell
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

Review 5.  Clodronic acid formulations available in Europe and their use in osteoporosis: a review.

Authors:  Bruno Frediani; Luca Cavalieri; Giovanni Cremonesi
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 6.  Clodronate: new directions of use.

Authors:  Bruno Frediani; Ilaria Bertoldi
Journal:  Clin Cases Miner Bone Metab       Date:  2015-10-26

Review 7.  The role of bisphosphonates in diseases of childhood.

Authors:  Tarak Srivastava; Uri S Alon
Journal:  Eur J Pediatr       Date:  2003-09-11       Impact factor: 3.183

Review 8.  Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis.

Authors:  Serge C L M Cremers; Goonaseelan Pillai; Socrates E Papapoulos
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

9.  Circular RNA atlas in osteoclast differentiation with and without alendronate treatment.

Authors:  Jianbiao Lin; Shaofeng Ma; Cong Zhu; Changqing Chen; Weibin Lin; Canbin Lin; Guofeng Huang; Zhenqi Ding
Journal:  J Orthop Surg Res       Date:  2020-07-01       Impact factor: 2.359

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.